摘要
急性髓细胞白血病(AML)中造血干细胞和祖细胞的分化堵塞导致血细胞减少和死亡的高风险。大多数AML患者由于缺乏有效的细胞毒性和促分化物而产生抗药性。高MN1表达使AML患者预后差,并诱导阿糖胞苷和全反式维甲酸(ATRA)诱导的抗分化。采用高通量筛选,我们确定了二氢叶酸还原酶(DHFR)拮抗剂乙胺嘧啶能有效的诱导小鼠和人白血病细胞株凋亡和分化。口服药物治疗在两个异种移植小鼠模型中是有效的,并且专门针对人类AML细胞株白血病细胞和原代细胞,而健康人的CD34+细胞不受影响。PMT的抗白血病的影响可以通过过量的叶酸部分减弱,提示在AML中叶酸代谢的致癌作用。因此,我们的研究确定了乙胺嘧啶作为候选药物,应进一步评估在AML的治疗。
关键词: AML,细胞凋亡,分化和DHFR,高通量药物筛选
图形摘要
Current Cancer Drug Targets
Title:Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening
Volume: 16 Issue: 9
Author(s): Amit Sharma, Nidhi Jyotsana, Courteney K. Lai, Anuhar Chaturvedi, Razif Gabdoulline, Kerstin Görlich, Cecilia Murphy and Jan E. Blanchard, Arnold Ganser, Eric Brown, John A. Hassell, R. Keith Humphries, Michael Morgan, Michael Heuser
Affiliation:
关键词: AML,细胞凋亡,分化和DHFR,高通量药物筛选
摘要: Hematopoietic stem and progenitor cell differentiation are blocked in acute myeloid leukemia (AML) resulting in cytopenias and a high risk of death. Most patients with AML become resistant to treatment due to lack of effective cytotoxic and differentiation promoting compounds. High MN1 expression confers poor prognosis to AML patients and induces resistance to cytarabine and alltrans-retinoic acid (ATRA) induced differentiation. Using a high-throughput drug screening, we identified the dihydrofolate reductase (DHFR) antagonist pyrimethamine to be a potent inducer of apoptosis and differentiation in several murine and human leukemia cell lines. Oral pyrimethamine treatment was effective in two xenograft mouse models and specifically targeted leukemic cells in human AML cell lines and primary patient cells, while CD34+ cells from healthy donors were unaffected. The antileukemic effects of PMT could be partially rescued by excess folic acid, suggesting an oncogenic function of folate metabolism in AML. Thus, our study identifies pyrimethamine as a candidate drug that should be further evaluated in AML treatment.
Export Options
About this article
Cite this article as:
Amit Sharma, Nidhi Jyotsana, Courteney K. Lai, Anuhar Chaturvedi, Razif Gabdoulline, Kerstin Görlich, Cecilia Murphy and Jan E. Blanchard, Arnold Ganser, Eric Brown, John A. Hassell, R. Keith Humphries, Michael Morgan, Michael Heuser , Pyrimethamine as a Potent and Selective Inhibitor of Acute Myeloid Leukemia Identified by High-throughput Drug Screening, Current Cancer Drug Targets 2016; 16 (9) . https://dx.doi.org/10.2174/1568009616666160617103301
DOI https://dx.doi.org/10.2174/1568009616666160617103301 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Unleashing the Guardian: The Targetable BCR-ABL/HAUSP/PML/PTEN Network in Chronic Myeloid Leukemia
Current Drug Targets Ribonucleases, Nucleases and Antiangiogenins in Antiproliferative Activities
Current Signal Transduction Therapy Cyclodepsipeptides - Potential Drugs and Lead Compounds in the Drug Development Process
Current Medicinal Chemistry Beyond Photodynamic Therapy: Light-Activated Cancer Chemotherapy
Current Medicinal Chemistry Tubulin-Targeting Agents in Hybrid Drugs
Current Medicinal Chemistry Genome-wide Analysis of Myelodysplastic Syndromes
Current Pharmaceutical Design Exploring and Exploiting Biologically Relevant Chemical Space
Current Drug Targets Hemopoiesis in Ph-Negative Chronic Myeloproliferative Disorders
Current Stem Cell Research & Therapy Applications of 211At and 223Ra in Targeted Alpha-Particle Radiotherapy
Current Radiopharmaceuticals Carbon Nanotubes: Classification, Method of Preparation and Pharmaceutical Application
Current Drug Delivery Delivery Methods of Camptothecin and Its Hydrosoluble Analogue Irinotecan for Treatment of Colorectal Cancer
Current Drug Delivery Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Advances in Photodynamic Therapy of Cancer
Current Cancer Therapy Reviews Insects Antiviral and Anticancer Peptides: New Leads for the Future?
Protein & Peptide Letters Involvement of Mast Cells in Angiogenesis and Chronic Inflammation
Current Drug Targets - Inflammation & Allergy The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism The Acute Phase Protein α1-Acid Glycoprotein: A Model for Altered Glycosylation During Diseases
Current Protein & Peptide Science New Opportunities to Treat the T315I-Bcr-Abl Mutant in Chronic Myeloid Leukaemia: Tyrosine Kinase Inhibitors and Molecules that Act by Alternative Mechanisms
Current Medicinal Chemistry Novel Mechanisms of Anticancer Activities of Green Tea Component Epigallocatechin- 3-Gallate
Anti-Cancer Agents in Medicinal Chemistry A Combination of Two Antioxidants (An SOD Mimic and Ascorbate) Produces a Pro-Oxidative Effect Forcing Escherichia coli to Adapt Via Induction of oxyR Regulon
Anti-Cancer Agents in Medicinal Chemistry